[1] ZANG H M， ZHOU J P， LV H X. Current progress in research on thalidomide[J]. Prog Pharm Sci（药学进展， 2008， 32（1：21-27.
[2] YU S H， JI H. Anti-neoplastic progress in drug combination of thalidomide[J]. Chin J Clin Pharmacol Ther， 2009， 14 (2：230-236.
[3] ERIN R L， SMITH N F， COX M C， et al. Thalidomide metabolism and hydrolysis： Mechanisms and implications[J]. Curr Drug Metab， 2006， 7（6： 677-685.
[4] GORDON R M， MICHAEL F， ANDRADA T C， et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer[J]. Crit Rev Oncol Hematol，2003（46：49-57.
[5] ANDO Y， PRICE D K， DAHUT W L， et al. Pharmacogenetic association of CYP2C19 genotype with in vivo metabolisms and drug effects of thalidomide[J]. Cancer Biol Ther， 2002（1：669-673.
[6] WILLIAMS M L， BHARGAVA P， CHERROUK I， et al. A discordance of the cytochrome P450 2C19 genotype and ph enotype in patients with advanced cancer[J]. Br J Clin Pharmacol， 2000（49：485-488.
[7] NIZAR S， SAMI L， KHELLA. A prospective double-blind， placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration[J]. J Clin Neurosci， 2010，17（5：571-573.
[8] FIONA J F， MICHAL V， JEFFREY C， et al. Thalidomide neuropathy in childhood[J]. Neuromuscul Disord， 2005， 15： 172-176.
[9] XAVIER O， MARTA R L， MARISA C， et al. Stroke in a multiple myeloma patient treated with thalido mide[J]. J Stroke Cereb Dis， 2006， 15(6： 283-285.
[10] THADANI N A, MCNAMEE J P, WINN L M. Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells[J]. Pharmacol Res， 2006，54（2：91-96.
[11] EMA M， ISE R， KATO H. Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide[J]. Reprod Toxicol， 2010， 29（1： 49-56.
[12] INVERNIZZI R， TRAVAGLINO E， AMICI M D. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes[J]. Leuk Res， 2005, 29（6：641-647.
[13] YI-SHIN K D， TIMMINS P， BLANK S V， et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma： A brief communication from the New York Phase II consortium[J]. Gynecol Oncol， 2006，100（1： 160-165.
[14] CHAN J K，MANUEL M R， CIARAVINO G， et al. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma[J]. Gynecol Oncol， 2006，103（3： 919-923.
[15] LEE S M, JAMES L, BUCHLER T， et al. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer[J]. Lung Cancer， 2008，59（3：364-368.
[16] PACHECO A V, RASILA K，LEE S J， et al. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma： FUNIL-retinoid and the FUNIL-thalidomide protocols[J]. Urol Oncol， 2008，26（6： 610-615.
[17] RICKA O， BRAUNB T， SIEGERT W， et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours[J]. Eur J Cancer， 2006，42（12：1775-1779.
[18] LREZ-AGUILAR E, SEPULVEDA-VILDOSLA A C， BETANIOS-CABRERA Y， et al. Phase II study of metronomic chemotherapy with thalidomide， carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children[J]. Arch Med Res， 2008,39（7： 655-662.
[19] HOLSTEIN S A, TONG H, HOHL R J. Differential activities of thalidomide and isoprenoid biosynthe tic pathway inhibitors in multiple myeloma cells[J]. Leuk Res， 2010，34（3： 344-351.
[20] EFSTATHIOS K， MELETIONS A D. Thalidomide in the treatment of multiple myeloma[J]. Best Pract Res Clin Haematol， 2007， 20(4： 681-699.
[21] DMOSZYNSKA A, WAITER-CRONECK A, HUS I， et al. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide， thalidomide， dexamethasone regimen in patients with multiple myeloma——A report by the Polish Myeloma Study Group[J]. Leuk Res， 2010, 34（10：1330-1335.
[22] DU J， YUAN Z， ZHANG C，et al. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone[J]. Leuk Res， 2010，34（11：1453-1458.
[23] SHANNON E J， SANDOVAL F. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis[J]. Int J Immunopharmacol， 2010，10（4：487-492.
[24] GARCIA-CARRASCO M, FUENTES-ALEXANDRO S, ESCRCEGA R O， et al. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis[J]. Joint Bone Spine， 2007，74（5： 500-503.
[25] PALENCIA G， CALDERON A， SOTELO J. Thalidomide inhibits pentylenetetrazole-induced seizures[J]. J Neurol Sci， 2007，258（1-2：128-131.
[26] VALE M L, CUNHA F Q, BRITO A C， et al. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation[J]. Eur J Pharm， 2006，536（3： 309-317.
[27] DONG J P. Overview of thalidomide revaluation and approval in the developed countries[J]. China Licensed Pharmacist（中国执业药师， 2008， 5(8： 35-37.
[28] ALAN F L. Lenalidomide-the phoenix rises[J]. New England J Med， 2007， 357(21：2183.